The study is designed to determine the absorption, distribution, metabolism and elimination (ADME) of BIA 28-6156 in humans, further explore the PK of BIA 28-6156, evaluate the extent of distribution of total radioactivity into blood cells, provide additional safety and tolerability information and collect samples for metabolite profiling and structural identification.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Mass balance recovery of total radioactivity in all excreta (urine and faeces)
Timeframe: Urine: Day 1 through Day 11, Faeces: Day -1 through Day 11
Collection of urine and faecal samples for total radioactivity
Timeframe: Urine and Faeces: Pre-dose until 288 hours post-dose
Collection of plasma samples for metabolite profiling
Timeframe: Pre-dose until 240 hours post-dose
Collection of plasma samples for structural identification
Timeframe: Pre-dose until 240 hours post-dose
Collection of whole blood samples for total radioactivity
Timeframe: Pre-dose until 240 hours post-dose